Male gender results in more severe lupus nephritis

Gender may produce different characteristics in the manifestation of systemic lupus erythematosus (SLE). The present study investigated the influence of gender on clinical, laboratory, autoantibodies and histopathological classes of lupus nephritis (LN). As much as 81 patients diagnosed with SLE (ACR criteria) and active nephritis, who underwent renal biopsy between 1999 and 2004, and who had frozen serum samples and clinical data available from the time of biopsy, were selected for this study. The presence of anti-P and antichromatin antibodies was measured using ELISA, and anti-dsDNA was measured using indirect immunofluorescence. All of the renal biopsies were reviewed in a blinded manner by the same expert renal pathologist. The charts were extensively reviewed for demographic and renal features obtained at the time of the biopsy. Of the 81 patients (13.6%), 11 were male SLE patients. Both male and female lupus patients were of similar age and race, and had similar durations of lupus and renal disease. The female patients had more cutaneous (95.7 vs. 45.5%, P = 0.0001) and haematological (52.9 vs. 18.2%, P = 0.04) involvements than the male SLE patients. In addition, the articular data, central nervous system analyses, serositis findings and SLEDAI scores were similar in both experimental groups. Positivity for anti-dsDNA, anti-ribosomal P and antichromatin did not differ between the two groups, and both groups showed similarly low C3 or C4 serum levels. Our analysis indicated that no histopathological class of LN was predominant in both males and females. Interestingly, the serum creatinine levels were higher in the male SLE patients compared to the female SLE group (3.16 +/- A 2.49 vs. 1.99 +/- A 1.54 mg/dL, P = 0.03), with an increased frequency of high creatinine (81.8 vs. 47.1%, P = 0.04) as well as renal activity index (7.6 +/- A 3.5 vs. 4.8 +/- A 3.5, P = 0.02). In addition, whilst the mean levels of proteinuria, cylindruria and serum albumin were markedly altered, they were comparable between both lupus men and women. Moreover, the frequencies of dialysis, renal transplantation and death were similar between the two groups. These data suggest that male patients had a more severe LN compared to women diagnosed with this renal abnormality.

Detection of anti-Giardia lamblia serum antibody among children of day care centers

OBJETIVES: To detect anti-Giardia lamblia serum antibodies in healthy children attending public day care centers and to assess serological tests as tools for estimating the prevalence of G. lamblia in endemic areas. METHODS: Three separate stool specimens and filter paper blood samples were collected from 147 children ranging from 0 to 6 years old. Each stool sample was processed using spontaneous sedimentation and zinc sulfate flotation methods. Blood samples were tested by indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) for Giardia IgG. RESULTS AND CONCLUSIONS: Of 147 individuals tested, 93 (63.3%) showed Giardia cysts in their feces. Using IIF and ELISA, serum antibodies were detected in 93 (63.3%) and 100 (68%) samples , respectively. Sensitivity of IIF and ELISA was 82% and 72%, respectively. However, ELISA revealed to be less specific (39%) than IIF (70%). IIF also showed a higher concordance with microscopic examination than ELISA.

ANTI M. leprae IgM ANTIBODY DETERMINATION BY ULTRAMICROIMMUNOENZYMATIC (UMELISA HANSEN) FOR THE DIAGNOSIS AND MONITORING LEPROSY

The relationship between the IgM antibody response, antigenic load as well as the clinical improvement after chemotherapy was studied in order to obtain useful data for the early diagnosis and monitoring leprosy. A level of 82% (94/115) agreement was obtained between IgM UMELISA HANSEN and slitskin smear examination. Discrepant results were observed in 16 patients who showed positive IgM response despite negative by the skin smear examination. In these patients, the IgM response was seen to be associated to the early signal for bacilli recurrence in the skin. In one of these patients the presence of bacilli was demonstrated in the skin, two months after IgM antibodies being detected by UMELISA HANSEN. Also in one of the treated patients positive by both diagnostic techniques, a remarkable decrease in the IgM antibody levels was seen, correlating with a significant clinical improvement. Moreover it was found a direct relationship between the IgM antibody response and bacterial antigenic load, regardless the time elapsed in the disease's evolution.

Prevention of bone marrow graft failure by an anti LFA-1 monoclonal antibody

Graft rejection is the major cause of failure of HLA mismatched bone marrow transplantation because of residual host immunity. we have proposed to use a monoclonal murine antibody specific for the LFA-1 molecule (25-3) to prevent graft failure in HLA mismatched bone marrow transplantation (BMT). The rationale for this approach is three fold: LFA-1 deficient patients (3/3) do not reject HLA mismatched BMT; anti LFA-1 blocka in vitro the induction of T cell responses and T/ non T cytotoxic functions; LFA-1 is not expressed by other cells than leucocytes. We have accordingly treated twenty two patients with inherited diseases and 8 with leikemia. The bone marrow was T cells depled by E rosetting of Campath antibody. The antibody was given at days -3, -1, +1, +3, +5 at dose of .1 mg/kg/d for the first 9 and then .2mg/kg/d from day -3 to +6. Engraftment occured in 23/30 patients as shown by at least HLA typing. Hematological recovery was rapid, GVH was limited. Side effects of antibody infusion included fever and possibly an increased incidence of early bacteral infection (sepsis, 1 death). Immunological reconstitution occured slowly leading in six cases to EBV-induced B cell poliferation (1 death and in two others to transient auto immune hemolytic anemia. There has been only one secondary graft rejection. Sisteen patients are alive 3 to 26 months post transplant with functional grafts. Although the number of patients treated is still low the absence of late rejection so far, gives hope for long term maintenance of the graft using anti LFA-1. Since the antibody is an IgG 1 unable to bind human complement, and since it is known to inhibit phagocytosis, there is a good suggestion that 25-3 act through functional blocking of host T and non T luymphocytes at both induction and effector levels.

The inhibitory effect of photodynamic therapy and of an anti-VCAM-1 monoclonal antibody on the in vivo growth of C6 glioma xenografts

We investigated the effect of photodynamic therapy (PDT) and of an anti-vascular cell adhesion molecule-1 (VCAM-1) monoclonal antibody on the in vivo growth of C6 glioma. Seven days after inoculation with C6 cells, adult male Wistar rats weighing 280-300 g with MRI-confirmed glioma were randomly assigned to 4 groups (N = 15 per group): PDT + VCAM-1 antibody group; PDT group; VCAM-1 antibody group; control group. Eight days after inoculation, hematoporphyrin monomethyl ether (HMME) was administered as a photosensitizer and PDT was performed at 630 nm (illumination intensity: 360 J/cm²) for 10 min. VCAM-1 antibody (50 µg/mL) was then administered (0.5 mL) through the tail vein every other day from day 8 to day 16. At day 21, 5 rats in each group were sacrificed and cancers were harvested for immunohistochemistry and Western blot assay for the detection of VCAM-1, and TUNEL assay was used to detect apoptosis. Survival and tumor volume were recorded in the remaining 10 rats in each group. In the PDT group, tumor growth was significantly suppressed (67.2%) and survival prolonged (89.3%), accompanied by an increase in apoptosis (369.5%), when compared to control. Furthermore, these changes were more pronounced in the PDT + VCAM-1 antibody group. After PDT, VCAM-1 expression was markedly increased (121.8%) and after VCAM-1 monoclonal antibody treatment, VCAM-1 expression was significantly reduced (58.2%). PDT in combination with VCAM-1 antibody can significantly inhibit the growth of C6 glioma and prolong survival. This approach may represent a promising strategy in the treatment of glioma.

Autoimmune disease and multiple autoantibodies in 42 patients with RASopathies

The association of RASopathies [Noonan syndrome (NS) and Noonan-related syndromes] and autoimmune disorders has been reported sporadically. However, a concomitant evaluation of autoimmune diseases and an assessment of multiple autoantibodies in a large population of patients with molecularly confirmed RASopathy have not been performed. The clinical and laboratory features were analyzed in 42 RASopathy patients, the majority of whom had NS and five individuals had Noonan-related disorders. The following autoantibodies were measured: Anti-nuclear antibodies, anti-double stranded DNA, anti-SS-A/Ro, anti-SS-B/La, anti-Sm, anti-RNP, anti-Scl-70, anti-Jo-1, anti-ribosomal P, IgG and IgM anticardiolipin (aCL), thyroid, anti-smooth muscle, anti-endomysial (AE), anti-liver cytosolic protein type 1 (LC1), anti-parietal cell (APC), anti-mitochondrial (AM) antibodies, anti-liver-kidney microsome type 1 antibodies (LKM-1), and lupus anticoagulant. Six patients (14%) fulfilled the clinical criteria for autoimmune diseases [systemic lupus erythematous, polyendocrinopathy (autoimmune thyroiditis and celiac disease), primary antiphospholipid syndrome (PAPS), autoimmune hepatitis, vitiligo, and autoimmune thyroiditis]. Autoimmune antibodies were observed in 52% of the patients. Remarkably, three (7%) of the patients had specific gastrointestinal and liver autoantibodies without clinical findings. Autoimmune diseases and autoantibodies were frequently present in patients with RASopathies. Until a final conclusion of the real incidence of autoimmunity in Rasopathy is drawn, the physicians should be alerted to the possibility of this association and the need for a fast diagnosis, proper referral to a specialist and ultimately, adequate treatment. (c) 2012 Wiley Periodicals, Inc.

Na 1 Nachlass Max Horkheimer, 662 - "Research Project on Anti-Semitism" (p. IX 92.1b-IX 92.1d)

"International Institute of Social Research: Research-Project on Anti-Semitism" (1939-42) (veröffentlicht in Studies in Philosophy and Social Science Bd. IX, 1941, S. 124-143): 1. "Research Project on Anti-Semitism", b) Typoskript, 38 Blatt, c) Typoskript, 38 Blatt, d) Typoskript mit eigenhändigen und handschriftlichen Korrekturen, 46 Blatt;

Na 1 Nachlass Max Horkheimer, 663 - "Research-Project on Anti-Semitism" (p. IX 92.1e-IX 92.7)

International Institute of Social Research: Research-Project on Anti-Semitism" (1939-42) (veröffentlicht in Studies in Philosophy and Social Science Bd. IX, 1941, S. 124-143):; 1. e) Typoskript, 46 Blatt, f) Teilstück, Typoskript, 1 Blatt, g) deutsche Fassung, Typoskript, 43 Blatt; 2. Entwurf, deutsch, Typoskript mit eigenhändigen Korrekturen, 6 Blatt; 3. Über das Forschungsprojekt zum Antisemitismus, Typoskript, deutsch, 1 Seite fehlt, 38 Blatt; 4. Zitate aus Werken Friedrich Nietzsches über Jude, Antisemitismus, Rasse, Heinrich Heine, Typoskript, 18 Blatt; 5. Stichwortverzeichnis zu 4., handschriftliche Notizen, 10 Blatt; 6. Über Nietzsche, eigenhändige und handschriftliche Notizen zu 4., 3 Blatt; 7. "Supplementary Statement Dec. 1942", enthält unter anderem Abschriften bzw. Kopien von Briefen der Sponsoren des Projekts und ein Memorandum über die Tätigkeiten des Instituts 1939-41, a) als Typoskript vervielfältigt, 51 Blatt und 1 Sonderdruck: "International Institute of Social Research: A Report on Its History, Aims and Activities 1933-38", b) Typoskript und Photokopien, 28 Blatt und 2 Sonderdrucke: wie bei 7.a), außerdem "Research Project on Antisemitism", Studies in Philosophy and Social Science IX, 1941;

Na 1 Nachlass Max Horkheimer, 664 - "Research-Project on Anti-Semitism" (p. IX 92.8-IX 100)

International Institute of Social Research: Research-Project on Anti-Semitism" (1939-42) (veröffentlicht in Studies in Philosophy and Social Science Bd. IX, 1941, S. 124-143): 8. American Jewish Committee, Library: 1 Brief mit Unterschrift an Institute of Social Research, New York, 01.05.1941, 1 Brief mit Unterschrift von Institute of Social Research, New York, 3.5.1941, 2 Blatt; "Re: Anti-Semitism Project of the Institute of Social Research" (1941), Typoskript, 2 Blatt; "Remarks to the new form of the Project on Anti-Semitism" (27.10.1942), Typoskript, 10 Blatt; "Memorandum on a Research-Project on Anti-Semitism" (30.10.1942), a) Typoskript, 14 Blatt, b) Typoskript mit handschriftlichen Bemerkungen, 14 Blatt; Robert S. Lynd: Kommentar zu einer Beschreibung des Antisemitismus-Projekts vom 06.12.1942, Typoskript, englisch, mit handschriftlichen Korrekturen, 3 Blatt; "Outline of a Research Project on Anti-Semitism, prepared for the American Jewish Committee" (15.12.1942), a) Typoskript, 17 Blatt, b) Typoskript, 18 Blatt, c) Teilstück, Typoskript mit handschriftlichen Bemerkungen, 10 Blatt; "Memorandum on the Project on Antisemitism" (30.12.1942), a) Typoskript, 17 Blatt, b) Typoskript mit handschriftlichen Ergänzungen, 16 Blatt; "Some Methodological Errors in the Study of Antisemitism" (Januar 1943), Typoskript, 6 Blatt; "Intermediate Joint Meeting of the Institute of Social Research and the American Jewish Committee", Sitzungsprotokolle 01.03. - 27.07. 1943, Typoskripte mit handschriftlichen Korrekturen, 100 Blatt;

Na 1 Nachlass Max Horkheimer, 665 - "Research Project on Anti-Semitism" (p. IX 101-IX 112)

Institute of Social Research; "Research Project on Anti-Semitism. General Statement of Scope of Project, Fields to be investigated, First Assignements, Plan of Operation, Joint Conferences" (15.3.1943), a) Typoskript, 5 Blatt, b) Typoskript, 3 Blatt, c) Typoskript mit handschriftlichen Ergänzungen, 5 Blatt; Institute of Social Research: "Notes on Some Methodological Principles and Some Tentative Assumptions for the Work of the Anti-Semitism Project" (15.3.1943), Typoskript, 3 Blatt; "Project on Anti-Semitism. Excerpt from a letter of D.R. (American Jewish Committee), dated 3/31/43" (31.03.1943), Typoskript mit handschriftlichen Ergänzungen, 2 Blatt; Institute of Social Research: "Research Project on Anti-Semitism. General Statement of Scope of Project, Fields to be investigated, First Assignements etc. Supplement: Los Angeles Group" (26.4.1943), a) Typoskript mit handschriftlichen Ergänzungen, 13 Blatt, b) Typoskript, 13 Blatt, c) Typoskript, 8 Blatt; Heinz Langerhans: "Methods to Evaluate the Attitude of Different Sections of the German Population toward Institutionalized Antisemitism" (6.5.1943), Typoskript mit eigenhändiger Korrektur, 5 Blatt; "Discussion with Messrs. George Mintzer and Newman Levy on present day U.S.A. Antisemitism" (5.3.1943), a) Typoskript, 4 Blatt b) Typoskript mit handschriftlichen Korrekturen, 4 Blatt; Re.: Antisemitism Project. Statement of Expense 15.03.1943 - 15.06.1943, Preliminary Budget 15.06.1943 - 15.03.1944, Aufstellungen für das American Jewish Committee, 15.06.1943, 4 Blatt; Paul Massing: "Some Notes to Fineberg's 'Overcoming Antisemitism'" (16.06.1943), Typoskript, 4 Blatt; "Luncheon with Mr. Hexter. Present: Dr. Pollock, Weil, Gurland, Massing and Mr. Hexter. Purpose: Discussion of S.A. Fineberg's book 'Overcoming Antisemitism'" (17.06.1943), Typoskript, 2 Blatt; "Luncheon with Mr. R.C. Rothschild in the Yale Club", Über Antisemitismus in den USA, 28.6.1943, Typoskript mit handschriftlichen Korrekturen, 1 Blatt; Friedrich Pollock: Memoranden über Besprechungen mit R.C. Rothschild, betreffs Anti-Semitism-Project (September 1943): 1. "Remarks of Mr. Rothschild concerning our Psychological Study in a meeting between him, P. and L." (21.9.1943); 2. "Memorandum on work's progress of Anti-Semitism-Project" (15.09.1943), Typoskript, 1 Blatt; 3. "Meeting R.C. Rothschild and Pollock", (15.09.1943), Typoskript, 2 Blatt; 4. "Memorandum No. 1" (14.09.1943), Typoskript, 1 Blatt; "Memorandum re: Antisemitism Project" (29.10.1943), Typoskript mit handschriftlichen Ergänzungen, 2 Blatt;

Na 1 Nachlass Max Horkheimer, 666 - "Research Project on Anti-Semitism" (p. IX 113-IX 118)

Max Horkheimer (?): "Why Research on Antisemitism?" (12.11.1943), a) Typoskript, 8 Blatt, b) Typoskript mit eigenhändigen Korrekturen und handschriftlichen Ergänzungen, 7 Blatt, c) Teilstück, Typoskript, 1 Blatt; Isaque Graeber: "Modern Antisemitism in Western Society. A Comperative Study of 'Critical Situations'" (1943), Typoskript mit eigenhändigen Korrekturen, 118 Blatt; Institute of Social Research: "Report on Isaque Graebers Study on Modern Antisemitism in Western Society. A Comperative Study of 'Critical Situations'" (24.11.1943), Typoskript, 73 Blatt; Institute of Social Research: "The Project of Political Antisemitism" (30.11.1943) a) Typoskript mit handschriftlichen Ergänzungen, 29 Blatt, b) Kurzfassung, Typoskript, 6 Blatt; "Memorandum to John Doe. Subject: Research Project on Antisemitism" (30.11.1943), Typoskript mit handschriftlichen Ergänzungen, 2 Blatt; Institute of Social Research: "Project on Antisemitism. Studies Completed or in Preparation" (Dezember 1943), Entwurf, Typoskript, 2 Blatt;

Identification of specific Rp-phosphate oxygens in the tRNA anticodon loop required for ribosomal P-site binding

tRNA binding to the ribosomal P site is dependent not only on correct codon–anticodon interaction but also involves identification of structural elements of tRNA by the ribosome. By using a phosphorothioate substitution–interference approach, we identified specific nonbridging Rp-phosphate oxygens in the anticodon loop of tRNAPhe from Escherichia coli which are required for P-site binding. Stereo-specific involvement of phosphate oxygens at these positions was confirmed by using synthetic anticodon arm analogues at which single Rp- or Sp-phosphorothioates were incorporated. Identical interference results with yeast tRNAPhe and E. coli tRNAfMet indicate a common backbone conformation or common recognition elements in the anticodon loop of tRNAs. N-ethyl-N-nitrosourea modification–interference experiments with natural tRNAs point to the importance of the same phosphates in the loop. Guided by the crystal structure of tRNAPhe, we propose that specific Rp-phosphate oxygens are required for anticodon loop (“U-turn”) stabilization or are involved in interactions with the ribosome on correct tRNA–mRNA complex formation.

Anti-idiotype RNA selected with an anti-nuclear export signal antibody is actively transported in oocytes and inhibits Rev- and cap-dependent RNA export

The anti-idiotype approach is based on the assumption that an antibody specific for a receptor-binding domain of a ligand could be structurally related to the receptor. Therefore, a structural mimic of a receptor-binding domain, selected with an anti-ligand antibody, might be a functional substrate for the receptor. This hypothesis was addressed here by generating antibodies recognizing the Rev-nuclear export signal (NES). A functional NES is required for active export, presumably by interacting directly or indirectly with the nuclear pore complex. Anti-NES antibodies were used to isolate RNA mimics of the NES peptide from combinatorial RNA libraries. The RNA-mimics are exported actively, block Rev-dependent export of a reporter RNA, and inhibit cap-dependent U1 snRNA export in Xenopus oocytes, properties previously reported for NES-peptide conjugates.